Skip to main content
Vericel Corp logo

Vericel Corp — Investor Relations & Filings

Ticker · VCEL ISIN · US92346J1088 LEI · 54930076YM3PLTDR4B91 US Manufacturing
Open in API
Filings indexed 1,130 across all filing types
Latest filing 2013-03-18 Regulatory Filings
Country US United States of America
Listing US VCEL

About Vericel Corp

https://vcel.com/

Vericel Corporation is a biopharmaceutical company that develops, manufactures, and commercializes advanced cell therapies for the sports medicine and severe burn care markets. The company's portfolio is centered on autologous (patient-specific) cell-based products. Key commercial products include MACI® (autologous cultured chondrocytes on porcine collagen membrane), a tissue-engineered product for the repair of symptomatic cartilage defects of the knee, and Epicel® (cultured epidermal autografts), a permanent skin replacement for patients with severe burns. Additionally, Vericel holds the exclusive North American commercial rights for NexoBrid®, a biological orphan product used for the removal of eschar in adults with deep partial-thickness or full-thickness thermal burns.

Recent filings

Filing Released Lang Actions
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC. It registers additional shares under an employee benefit plan (the 2009 Omnibus Incentive Plan). The text includes details about the registration fee, incorporation by reference of prior filings, indemnification provisions, and legal disclaimers typical of a securities registration statement. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2013-03-18 English
10-K
Annual Report FY 2012
2013-03-18 English
FORM 8-K FILING DOCUMENT
Earnings Release Classification · 95% confidence The document is a Form 8-K filing dated March 18, 2013, which is a current report filed with the SEC to announce material events. The text specifically mentions Item 2.02 "Results of Operations and Financial Condition" and references a press release attached as Exhibit 99.1. The document itself does not contain detailed financial statements or comprehensive financial data but rather announces the issuance of a press release with results. This aligns with an Earnings Release (ER) type, which is typically an initial announcement of quarterly or periodical financial results. The document length is short (2588 characters), and it is a current report announcing financial results, not a full annual or interim report. Therefore, the best classification is Earnings Release (ER).
2013-03-18 English
FORM 3 -
Director's Dealing
2013-03-08 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated March 4, 2013, reporting the appointment of a new President and CEO, Dominick C. Colangelo, and the departure of the interim CEO. It details the terms of the Employment Agreement and related compensatory arrangements. The key content is about changes in senior management and board-related appointments. There is no financial data or earnings information, nor is it a report or announcement of a report publication. The document fits the category of Board/Management Information (MANG) as it announces changes in the company's senior management.
2013-03-08 English
FORM 3 -
Director's Dealing
2012-12-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.